Advertisement

2018 ASTRO: Radiation Therapy Outcomes in African American Patients With Prostate Cancer

Advertisement

Key Points

  • Tumors from African American men were more likely to have indicators of increased sensitivity to radiation therapy: decreased expression of the double-strand DNA repair pathway, increased expression of immune pathways, and increased radiosensitivity as predicted by a 24-gene prostate cancer radiation sensitivity score developed by the research team.
  • African American patients in these trials had lower rates of biochemical cancer recurrence and distant metastasis, even after controlling for age, performance status, prostate-specific antigen, Gleason grade, T stage, N stage, and hormone therapy use.
  • Researchers commented that the findings, coupled with other recent analyses, confirm that the seeming racial disparities for prostate cancer are rooted more in societal causes than biology.

A new analysis of genetic data from a large prospective registry and clinical data from several randomized trials indicates that African American patients may have comparatively higher cure rates when treated with radiation therapy than Caucasian patients. The study, which is the first report demonstrating improved prostate cancer outcomes for African American men, was presented by Spratt et al at the 60th Annual Meeting of the American Society for Radiation Oncology (ASTRO) and published in the International Journal of Radiation Oncology • Biology • Physics.

“Our findings suggest that African American race is not independently associated with worse prostate cancer outcomes,” said lead author Daniel Spratt, MD, Associate Professor and Chief of the Genitourinary Radiotherapy Program at the University of Michigan Rogel Cancer Center, in a statement. “When we started this project, we had the commonly held assumption that African American men harbor more aggressive disease that leads to lower survival rates. We were surprised, however, that they appear to be more responsive than Caucasian men to radiation therapy and have improved outcomes following this treatment.”

Cancer registries have reported that African American men appear to be at higher risk of dying from aggressive prostate cancer, with an incidence rate almost 60% higher and a mortality rate 2 to 3 times greater than Caucasian men. What remains unclear, however, are how socioeconomic vs biologic factors contribute to these disparities.

Study Design and Findings

The two-part study from Dr. Spratt’s team examined biological factors that drive responses to prostate cancer treatment and may explain the disparity in outcomes. The team first investigated differences in how specific genes were expressed in tumor samples from 17,003 men (1,953, or 11.5%, African American) with prostate cancer, focusing on androgen receptor activity and sensitivity to radiation, as well as outcomes following radiation therapy.

Tumors with low androgen receptor activity were significantly more likely to develop distant metastases within 10 years (37% vs 17%, P = .008), and tumors from African American men were significantly more likely to have low androgen receptor activity (P < .001). Low androgen receptor activity was an independent predictor of distant metastasis, even after adjusting for Gleason grade, T stage, prostate-specific antigen (PSA) level, margin status after surgery, and lymph node invasion (P = .03).

Tumors from African American men also were more likely, however, to have indicators of increased sensitivity to radiation therapy: decreased expression of the double-strand DNA repair pathway (P < .001), increased expression of immune pathways (P < .001), and increased radiosensitivity as predicted by a 24-gene prostate cancer radiation sensitivity score developed by the research team. Increased radiotherapeutic sensitivity suggests that African American patients have improved outcomes when treated with radiation.

“Differences in gene expression between African American and Caucasian patients revealed that African American patients had lower DNA repair and more immunogenic tumors, both of which have been shown to predict better responses to radiation therapy,” said Dr. Spratt.

Next, researchers examined outcomes from 5,854 patients (19.3% African American) in 4 large NRG Oncology/RTOG randomized prostate cancer trials (NRG-RTOG 9202, 9408, 9413, and 9910). This meta-analysis showed that African American men treated with radiation therapy, compared to Caucasian men, were less likely to see their cancer return or spread.

Specifically, African American patients in these trials had lower rates of biochemical cancer recurrence (hazard ratio [HR] = 0.82, 95% confidence interval [CI] = 0.74–0.92; P = .0005) and distant metastasis (HR = 0.70, 95% CI = 0.57–0.86; P = .0008), even after controlling for age, performance status, PSA, Gleason grade, T stage, N stage, and hormone therapy use.

Study Implications

Dr. Spratt, who also co-chairs the radiobiology and radiotherapy working group for the Prostate Cancer Foundation, said the team’s findings, coupled with other recent analyses, confirm that the seeming racial disparities for prostate cancer are rooted more in societal causes than biology.

“Our results directly question previously held beliefs from population-based registry data that African American men independently have worse prostate cancer outcomes than Caucasian men,” he explained. “These findings strengthen the notion that most of the observed disparity found in population data sets regarding stage-for-stage outcomes between African American and Caucasian men are reflective of social constructs and not rooted in biology.”

He concluded, “Not only did both groups generally have similar prognoses, but African American men treated with radiation therapy actually had higher rates of cure and excellent outcomes.” 

The content in this post has not been reviewed by the American Society of Clinical Oncology, Inc. (ASCO®) and does not necessarily reflect the ideas and opinions of ASCO®.


Advertisement

Advertisement



Advertisement

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.